Evidence map›Paper›PMID 41090377›Full record

ArticleJournal of medicinal chemistry2025

Anirban Ghoshal, John D Sears, Mohammad Anwar Hossain, Edwin G Tse, Stefanie Howell, Jane E Burdick, Noah L Morales, Sabian A Martinez, Isabella Law, Zachary J Streblow and 5 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

  • Update of
    2025
5 · Who and what money

Authors and funding

15 authors.

Anirban GhoshalStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
John D SearsREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Mohammad Anwar HossainStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8684-8755
Edwin G TseStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Stefanie HowellStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jane E BurdickREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Noah L MoralesREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Sabian A MartinezREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Isabella LawREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Zachary J StreblowREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Daniel N StreblowREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Rafael M CouñagoStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-1847-5090
Nathaniel J MoormanREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Mark T HeiseREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Timothy M WillsonStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-4181-8223

Funding

Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5M
Request for a 500 MHz NMR console and nitrogen-cooled cryoprobeS10OD032476 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, ANDREW L · 2022 to 2022
$599k
NIAID NIH HHS U19 AI171292NIH HHS S10 OD032476
6 · The paper itself

Abstract

The emergence of mosquito-borne alphaviruses that cause chronic arthritis or encephalitis underscores the urgent need for broad-spectrum antiviral therapeutics. The viral nsP2 cysteine protease, which is essential for alphavirus replication, is a promising antiviral target. Vinyl sulfone covalent inhibitors potently inhibit nsP2 protease but suffer from glutathione reactivity and species-dependent systemic clearance catalyzed by glutathione

Indexed as

AlphavirusAntiviral AgentsCysteine Proteinase InhibitorsSulfonic AcidsViral Nonstructural ProteinsAnimalsHumansStructure-Activity RelationshipAntiviral AgentsCysteine Proteinase Inhibitorssulfamic acidSulfonic AcidsViral Nonstructural Proteins

Identifiers

PMID41090377
PMCPMC12621199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.